Tracking the impact of translational research in psychiatry: State of the art and perspectives

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Machado Vieira, Rodrigo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animal; Biomarker; Human; Personalized; Psychiatry; Research; Translational; Treatment

Indexed keywords

GLUCOCORTICOID RECEPTOR ANTAGONIST; GLUTAMIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; OPIATE RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST;

COGNITION; COMORBIDITY; DRUG INDUSTRY; DRUG RESEARCH; DSM-5; HEALTH CARE FINANCING; HEALTH CARE MANAGEMENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MEDICAL ETHICS; MENTAL DISEASE; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PSYCHIATRY; TRANSLATIONAL RESEARCH;

HUMANS; PSYCHIATRY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84865333268     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-175     Document Type: Note

References (31)

1. Butler D. Translational research: crossing the valley of death. Nature 2008, 12;453(7197):840-2.
2. Littman BH, Mario Di L, Plebani M, Marincola FM. What's next in translational medicine?. Clin Sci (Lond) 2007, 112(4):217-27.
3. Hurko O. The uses of biomarkers in drug development. Ann N Y Acad Sci 2009, 1180:1-10. 10.1111/j.1749-6632.2009.04946.x, 19906255.
4. Hurko O. Future drug discovery and development. Mol Genet Metab 2010, 100(Suppl 1):S92-96.
5. Cooksey D. A review of UK health research funding. 2006, Webcite: http://www.hmtreasury.gov.uk/d/pbr06_cooksey_final_report_636.pdf.
6. Insel TR. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry 2009, 66(2):128-33. 10.1001/archgenpsychiatry.2008.540, 19188534.
7. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a national institutes of health workshop. Control Clin Trials 2001, 22(5):485-502. 10.1016/S0197-2456(01)00153-2, 11578783.
8. Biomarkers definitions working group Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers definitions working group.
9. Keefe RS, Fox KH, Harvey PD, et al. Characteristic of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 2011, 125:161-168. 10.1016/j.schres.2010.09.015, 21075600.
10. Mcclure MM, Harvey PD, Goodman M, et al. Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacol 2010, 35:1356-1362.
11. Koychev IK, McMullen J, Lees R, et al. A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study. Eur Neuropsychopharmacol 2012, 22(7):469-81. 10.1016/j.euroneuro.2011.10.005, 22137565.
12. Gilles C, Schunck T, Erb G, et al. Human models as tools in the development of psychotropic drugs. Dialogues Clin Neurosci 2002, 4(4):377-87. 3181700, 22034241.
13. Dawson GR, Craig KJ, Dourish CT. Validation of experimental medicine methods in psychiatry: The P1vital approach and experience. Biochem Pharmacol 2011, 81:1435-1441. 10.1016/j.bcp.2011.03.013, 21440531.
14. Rupniak NM, Carlson EJ, Webb JK, Harrison T, Porsolt RD, Roux S, et al. Comparison of the phenotype of NK1Rÿ/ÿ mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 2001, 12:497-508. 10.1097/00008877-200111000-00011, 11742144.
15. Hafizi S, Chandra P, Cowen J. Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations. Br J Psychiatry 2007, 191:282-4. 10.1192/bjp.bp.107.037879, 17906236.
16. Sams-Dodd F. Strategies to optimize the validity of disease models in the drug discovery process. Drug Discov Today 2006, 11(7-8):355-63.
17. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci 2010, 13(10):1161-9. 10.1038/nn.2647, 20877280.
18. Machado-Vieira R, Kapczinski F, Soares JC. Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28(2):209-24. 10.1016/j.pnpbp.2003.10.015, 14751416.
19. Wehling M. Translational medicine: science or wishful thinking?. J Transl Med 2008, 6:31. 10.1186/1479-5876-6-31, 2442586, 18559092.
20. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008, 69(6):946-58. 10.4088/JCP.v69n0610, 2699451, 18435563.
21. Alamo C, López-Muñoz F. New antidepressant drugs: beyond monoaminergic mechanisms. Curr Pharm Des 2009, 15(14):1559-62. 10.2174/138161209788168047, 19442173.
22. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7(2):137-51. 10.1038/nrn1846, 16429123.
23. Gottesman I, Gould TD. The Endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003, 160:636-645. 10.1176/appi.ajp.160.4.636, 12668349.
24. Ritsner MS. The handbook of neuropsychiatric biomarkers, endophenotypes and genes 2009, New York: Springer-Verlag, Molecular genetic and genomic markers, Volume IV.
25. Breier A. Developing drugs for cognitive impairment in schizophrenia. Schizophr Bull 2005, 31:816-822. 10.1093/schbul/sbi051, 16150959.
26. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3:711-6. 10.1038/nrd1470, 15286737.
27. Miller G. Is Pharma running out of brainy ideas?. Science 2010, 329:502-4. 10.1126/science.329.5991.502, 20671165.
28. Regier DA, Kuhl EA, Narrow WE, Kupfer DJ. Research planning for the future of psychiatric diagnosis. Eur Psychiatry 2011, [Epub ahead of print].
29. De Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacol 2009, 34:159-172.
30. Evans WE, Relling PV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-91. 10.1126/science.286.5439.487, 10521338.
31. Sarkar IN. Biomedical informatics and translational medicine. J Transl Med 2010, 8:22. 10.1186/1479-5876-8-22, 2837642, 20187952.